Children as a special population at risk--quinolones as an example for xenobiotics exhibiting skeletal toxicity

Ralf Stahlmann1

  • 1Department of Toxicology, Institute of Clinical Pharmacology and Toxicology, Benjamin Franklin Medical Center, Freie Universität Berlin, Garystrasse 5, 14195 Berlin, Germany. ralf.stahlmann@medizin.fu-berlin.de

Archives of Toxicology
|December 20, 2002
PubMed

Insights

Immature mammals are highly sensitive to quinolone toxicity, which can cause cartilage and bone damage. This developmental toxicity is linked to the drug's magnesium-chelating properties, affecting young animals most severely.

Area of Science:

  • Toxicology
  • Developmental Biology
  • Pharmacology

Background:

  • The developing skeletal system in mammals exhibits unique sensitivities to xenobiotics.
  • Quinolones are a class of xenobiotics known to cause toxicity, particularly affecting cartilage, bone growth, and tendons.

Purpose of the Study:

  • To discuss the sensitivity of the immature skeletal system to xenobiotics, using quinolones as a case study.
  • To examine the developmental stage-dependent toxicity of quinolones on cartilage, bone, and tendons.

Main Methods:

  • Review of workshop discussions on regulatory toxicology and sensitive subgroups.
  • Analysis of animal experiments (dogs and rats) investigating quinolone effects at various developmental stages.
  • Consideration of clinical and experimental data on quinolone-induced tendopathies.

Main Results:

  • Chondrotoxicity of quinolones is dependent on the developmental stage, with peak sensitivity observed in young animals (e.g., 3-6 month old dogs, 3-6 week old rats).
  • Mature articular cartilage is not a target for quinolone toxicity.
  • Quinolones can damage the epiphyseal growth plate in early development, leading to irreversible bone damage and growth inhibition.
  • Tendopathies are another manifestation, with susceptibility in juveniles versus adults being unclear.

Conclusions:

  • The immature mammalian skeletal system is particularly vulnerable to quinolone-induced toxicity.
  • Developmental stage is a critical factor in quinolone toxicity, affecting cartilage, bone, and potentially tendons.
  • The magnesium-chelating properties of quinolones are implicated in the pathogenesis of these toxic effects, possibly involving radical formation and connective tissue damage.

Related Concept Videos

Inhibitors of Bacterial DNA Synthesis01:28

Inhibitors of Bacterial DNA Synthesis

Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...